Jason Kolbert said, "As co-chair of a dynamic panel at the World Stem Cell Summit, I look forward to raising investors' awareness of the opportunities for cell therapy companies to continue to develop and create value in the healthcare system by bringing new cost-effective therapies that can address unmet medical needs to the marketplace. We have seen many paradigm shifts in the biotechnology industry from monoclonal antibodies to viral disease. We foresee cell therapy as among the next great opportunities in the biotechnology space and are thrilled to be adding to our clinical assets, through our Amorcyte, Inc. merger, AMR-001 for the preservation of heart function post heart attack as we believe this will be an important asset that will help drive this paradigm shift."
Robert A. Preti, PhD, said, "PCT is excited to have these venues in the coming month to demonstrate our leadership in cell therapy development, manufacturing, quality assurance, regulatory consulting, and more. At PCT we embrace the need for regulation of cell therapies, and work constructively with the both the public and private sector where appropriate. With the development of NeoStem's cell therapeutics, we are taking the approach of developing therapies along the lines of more traditional drugs, so that the issues of potency, purity, identity, and stability - all of those components that pharmaceutical and biologics companies think about - are considered. It is in this regard that we value our relationships with professional associations such as AABB, whose membership is involved in
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved